Clinical Trials
4921
1157 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1908
Terminated
9
0.2%
Recruiting
600
12.2%
Suspended
3
0.1%
Available
2
0.0%
Withdrawn
3
0.1%
Active, not recruiting
117
2.4%
Completed
1928
39.2%
Unknown
1219
24.8%
Enrolling By Invitation
37
0.8%
Not yet recruiting
1003
20.4%
No approval data available
- A comprehensive review identifies TREM-1 as a central upstream amplifier of innate immune responses, rather than a mere initiator, drastically multiplying inflammatory cytokine release. - TREM-1's synergistic interaction with Toll-like receptors drives hyper-inflammation in sepsis, inflammatory arthritis, and neurodegenerative disorders including Alzheimer's and Parkinson's diseases. - The soluble form sTREM-1 shows strong promise as a prognostic biomarker for sepsis severity, while peptide antagonists LR12 and LP17 have demonstrated efficacy in preclinical models. - The inhibitor nanobiotide has advanced into human clinical trials, though translational hurdles including species-specific differences and risks of compromised protective immunity remain.
- A 24-month clinical trial comparing Scotchbond™ Universal Plus Adhesive to conventional universal adhesive demonstrated 100% success rate in cervical restorations, with superior marginal adaptation. - The radio-opaque universal adhesive, featuring a novel brominated dimethacrylate monomer, maintained excellent clinical performance while offering enhanced radiographic visibility. - Both adhesive systems showed reliable retention rates and no secondary caries, validating their effectiveness for treating cervical lesions in clinical practice.
